SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: Secreted SQ protein induces robust neutralization antibody in mice

Viral Immunology

Volumn 22, Issue 1, 2009, Pages 57-65

  Yan, Kexia ^a   Tan, Wenjie ^a   Wang, Huijuan ^a   Wang, Yue ^a   Zhang, Xiangmin ^a   Li, Yan ^b   Ruan, Li ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Public Health Agency of Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; GLYCOPROTEIN; INACTIVATED VIRUS VACCINE; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN CX; PROTEIN RBD; PROTEIN S; PROTEIN S 1; PROTEIN S II; PROTEIN S2Q; PROTEIN SQ; RO ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; DIAGNOSTIC TEST; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; LABORATORY DIAGNOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SARS CORONAVIRUS; SERUM; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINIA VIRUS; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; HELA CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

MUS; SARS CORONAVIRUS; VACCINIA VIRUS;

EID: 60149093886     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0064     Document Type: Article

References (59)

1. Bisht H, Roberts A, Vogel L, et al.: Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004;101:6641-6646.
2. Bisht H, Roberts A, Vogel L, Subbarao K, and Moss B: Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005;334:160-165.
3. Bosch BJ, van der Zee R, de Haan CA, and Rottier PJ: The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003;77:8801-8811.
4. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, and Collins PL: Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004;101:9804-9809.
5. Bukreyev A, Lamirande EW, Buchholz UJ, et al.: Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004;363:2122-2127.
6. Chan CP, Siu KL, Chin KT, Yuen KY, Zheng B, and Jin DY: Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2006;80:9279-9287.
7. Chen Z, Zhang L, Qin C, et al.: Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005;79:2678-2688.
8. Czub M, Weingartl H, Czub S, He R, and Cao J: Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005;23:2273-2279.
9. Deming D, Sheaha T, Heise M, et al.: Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006;3:e525.
10. Du L, Zhao G, Lin YG, et al.: Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2007;180:948-956.
11. Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, and Baric R: Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 2008;133:45-62.
12. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, and Schnell MJ: A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 2005;86:1435-1440.
13. Fang Q, Yang L, Zhu W, et al.: Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 2005;335:242-251.
14. Fouchier R, Hartwig N, Bestebroer T, Niemeyer B, de Jong J, Simon J, and Osterhaus A: A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA 2004;101:6212-6216.
15. Gao W, Tamin A, Soloff A, et al.: Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362:1895-1896.
16. Greenough TC, Babcock GJ, Roberts A, et al.: Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 2005;191:507-514.
17. Guan Y, Peiris JS, Zheng B, et al.: Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome. Lancet 2004;363:99-104.
18. Guan Y, Zheng BJ, He YQ, et al.: Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
19. He Y, Li J,. Heck S, Lustigman S, and Jiang S: Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome spike protein: implication for vaccine design. J Virol 2006;80:5757-5767.
20. He Y, Lu H, Siddiqui P, Zhou Y, and Jiang S: Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-4915.
21. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, and Jiang S: Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implications for developing subunit vaccine. Biochem Biophys Res Commun 2004;324:773-781.
22. Holmes KV: SARS-associated coronavirus. N Engl J Med 2003;348:1948-1951.
23. Huang J, Cao YN, Du JL, Bu XZ, Ma R, and Wu CY: Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 2007;25:6981-6991.
24. Ishii K, Hasegawa H, Nagata N, et al.: Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 2006;351:368-380.
25. Keng CT, Zhang A, Shen S, et al.: Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 2005;79:3289-3296.
26. Ksiazek TG, Erdman D, Goldsmith CS, et al. and the SARS Working Group: A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-1966.
27. Lau SK, Woo PC, Li KS, et al.: Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102:14040-14045.
28. Lee JS, Poo H, Han DP, et al.: Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 2006;80:4079-4087.
29. Li W, Moore MJ, Vasilieva N, et al.: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454.
30. Li W, Shi Z, Yu M, et al.: Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-679.
31. Li Y, Luo CQ, Li W, et al.: Structure-based preliminary analysis of immunity and virulence of SARS coronavirus. Viral Immunol 2004;17:528-534.
32. Liu RY, Wu LZ, Huang BJ, et al.: Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res 2005;112:24-31.
33. Marshall E, and Enserink M: Medicine. Caution urged on SARS vaccines. Science 2004;303:944-946.
34. Moss B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-11348.
35. Niedrig M, Leitmeyer K, Lim W, Peiris M, Mackenzie JS, and Zambon M: First external quality assurance of antibody diagnostic for SARS - new coronavirus. J Clin Virol 2005;34:22-25.
36. Normile D: Infectious diseases: mounting lab accidents raise SARS fears. Science 2004;304:659-661.
37. Peiris JS, Lai ST, Poon LL, et al.: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-1325.
38. Rota PA, Oberste MS, Monroe SS, et al.: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;5624:1394-1399.
39. Ruan L, Zheng HQ, Xu SC, et al.: Expression of both glycoprotein F and G of respiratory syncytial virus (RSV) in a single recombinant vaccinia virus. Chinese J Virol 1992;8:101-109.
40. Skowronski DM, Astell C, Brunham RC, et al.: Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 2005;56:357-381.
41. Spaan W, Cavanagh D, and Horzinek MC: Coronaviruses: structure and genome expression. J Gen Virol 1988;69:2939-2952.
42. Spiga O, Bernini A, Ciutti A, et al.: Molecular modeling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem Biophys Res Commun 2003;310:78-83.
43. Spruth M, Kistner O, Savidis-Dacho H, et al.: A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006;24:652-661.
44. Staib C, Drexler I, and Sutter G: Construction and isolation of recombinant MVA. Methods Mol Biol 2004;269:77-100.
45. Sui J, Li W, Murakami A, et al.: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human MAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004;101:2536-2542.
46. Sutter G, and Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851.
47. Tang L, Zhu Q, Qin E, et al.: Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 2004;23:391-394.
48. Tripet B, Howards MW, Joblings M, Holmes RK, Holmes KV, and Hodges RS: Structural characterization of the SARS-Coronavirus spike S fusion protein core. J Biol Chem 2004;279:20836-20849.
49. Tsao H, Liu GQ, Ruan L, Chu CM: Construction and application of plasmids containing bidirectional promoters of vaccinia virus. J Virol 1988;62:4832-4834.
50. Weingartl H, Czub M, Czub S, et al.: Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004;78:12672-12676.
51. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, and Dimitrov DS: The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003;312:1159-1164.
52. Yang Z, Werner HC, Kong W, Leung K, Traggiai E, Lanzavecchia A, and Nabel GJ: Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005;102:797-802.
53. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, and Nabel GJ: A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-564.
54. Yi CE, Ba L, Zhang L, Ho DD, and Chen Z: Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol 2005;79:11638-11646.
55. Zakhartchouk AN, Sharon C, Satkunarajah M, et al.: Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 2007;25:136-143.
56. Zeng F, Hon CC, Yip CW, et al.: Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: implications for the functional roles of S2 subunit. FEBS Lett 2006;580:5612-5620.
57. Zhang H, Wang G, Li J, et al.: Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 2004;78:6938-6945.
58. Zhao B, Jin NY, Wang RL, Zhang LS, and Zhang YJ: Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1. Viral Immunol 2006;19:518-524.
59. Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, and Cox M: A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006;24:3624-3631.